AstraZeneca’s new CEO removes R&D, commercial heads

LONDON (Reuters) – AstraZeneca’s new chief executive stamped his authority on the struggling drugmaker on Tuesday by removing the heads of research and commercial operations in a management revamp designed to speed decision-making. Pascal Soriot, who took the helm at Britain’s second-biggest pharmaceutical company in October, said the roles held by Martin Mackay and Tony Zook respectively had been eliminated and both men would leave the company at the end of January. …

QLT’s workforce cut, CEO quits after shareholder coup

TORONTO (Reuters) – Charting a new course after a boardroom coup, Canadian biotech company QLT Inc outlined plans on Monday to cut 68 percent of its workforce and find a new chief executive. The company’s new board, elected following a proxy battle in June, plans to sell or spin off parts of the company, return $100 million in capital to shareholders and focus on developing a treatment for several eye diseases that can cause blindness. …

1 2